Idéal Investisseur
Français English
CAC 40 : Market open
8 213,11 pts
+0.68%


Last updated : 27/04/2026 - 13h32
🏠 Home   ➤    Stock news

AB Science Stock Rises 2.73% After Testing Technical Support

AB Science shares increased by 2.73% on Wednesday, March 4, reaching 1.278 euros after testing the 1.24 euro level the previous day. This rebound occurs in a context of a significant decline over the last seven days, with a weekly performance of -5.19%. However, the Parisian biotech company has still managed to grow by more than 10% over three months.


AB Science Stock Rises 2.73% After Testing Technical Support

Technical Rebound After Support Level Test

The price of AB Science touched the level of 1.24 euros the previous day, which exactly corresponds to the support threshold identified by graphical analysis. This floor served as a pivot point, allowing the stock to recover right from the opening this Wednesday. The RSI, an indicator measuring the dynamics of a stock on a scale of 0 to 100, was at 33, close to the so-called oversold zone (below 30), signaling a potential bearish excess that could favor a short-term reversal. However, the price remains below its main moving averages: the MM50 is at 1.37 euros, the MM20 at 1.34 euros, and the MM200 at 1.29 euros, which is still slightly above the current price. This setup indicates that the underlying trend remains fragile, even though today's rebound offers a break after five consecutive sessions of decline.

Annual Performance and Market Sensitivity

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Over one year, AB Science's stock has declined by 7.12%, reflecting ongoing uncertainties around the clinical development of the company specializing in tyrosine kinase inhibitors. In the shorter term, the quarterly performance of +10.36% reflects a resurgence of interest observed at the beginning of the year, although no recent fundamental catalyst can be identified in the company's financial calendar. With a beta of 0.05, the stock shows very low sensitivity to general market movements. This decoupling explains why the biotech operates independently from the current geopolitical tensions affecting European indices. The monthly volatility, measured at 8.64, remains moderate for a stock in this segment. The next technical challenge lies at the 1.44 euro resistance level, whose crossing would condition a possible return to levels reached at the beginning of the year.

Related




Assurance vie
Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit